CERTIFICATE

IMPACT FACTOR 2021

Subject Area

  • Life Sciences / Biology
  • Architecture / Building Management
  • Asian Studies
  • Business & Management
  • Chemistry
  • Computer Science
  • Economics & Finance
  • Engineering / Acoustics
  • Environmental Science
  • Agricultural Sciences
  • Pharmaceutical Sciences
  • General Sciences
  • Materials Science
  • Mathematics
  • Medicine
  • Nanotechnology & Nanoscience
  • Nonlinear Science
  • Chaos & Dynamical Systems
  • Physics
  • Social Sciences & Humanities

Why Us? >>

  • Open Access
  • Peer Reviewed
  • Rapid Publication
  • Life time hosting
  • Free promotion service
  • Free indexing service
  • More citations
  • Search engine friendly

Role of badranjboya (Nepeta hindostana) in the prevention of atherosclerosis: single blind randomised controlled clinical trial

Author: 
Mohammad Azhar, Zarnigar, Sofi, G. and Mohammed Yasir
Subject Area: 
Health Sciences
Abstract: 

Atherosclerosis is the hardening and narrowing of the arteries and is caused by the slow build-up of plaque inside the walls of arteries. The clinical manifestations of atherosclerosis include myocardial infarction, stroke and sudden cardiac death. The prevalence of the disease is high, and approximately 50% of all deaths globally can be attributed to atherosclerosis. The concept of Dusumate Dam in Unani literature has been considered responsible for the development of Salabate Sharaeen (atherosclerosis) and Simane Mufrit (obesity). A randomized, single-blind, standard controlled clinical trial was conducted in National Institute of Unani Medicine Hospital Bangalore, with the objective of evaluating the efficacy of Badranjboya (Nepeta hindostana) as a cardio-protective drug. A total of 30 patients with risks of atherosclerosis were selected randomly and assigned into two groups 20 in test and 10 in control groups. Test group was treated with Badranjboya powder, 6 grams twice a day for 2 months whereas control group was treated with Garlic powder, 2 grams powder filled in gelatin capsules and given in to two divided doses for the same duration. The response was evaluated by the assessment of subjective parameters (palpitation, breathlessness, headache and chest pain) and objective parameter (blood pressure, lipid profile, haematocrit value and random blood sugar). The data was tabulated and analyzed by using apropriate statistical tests. Test group showed significant reduction in subjective parameters (p<0.01) and objective parameters like blood pressure, MDA concentration, whereas significant increase in HDL level (p<0.01) but changes in serum cholesterol, triglyceride, LDL, and haematocrit values were found statistically not significant in both groups. The effect of the drug was prominent on vessels wall. The overall improvement in test group was highly remarkable, without any clinically and statistically significant side effects or toxicity. Therefore, it can be concluded that Badranjboya has encouraging potential in the prevention of atherosclerosis and it may be combined with other treatment modalities like weight control in obese, physical therapy and dietary modification etc. for optimal results.

PDF file: 

CALL FOR PAPERS

 

ONLINE PAYPAL PAYMENT

IJMCE RECOMMENDATION

Advantages of IJCR

  • Rapid Publishing
  • Professional publishing practices
  • Indexing in leading database
  • High level of citation
  • High Qualitiy reader base
  • High level author suport

Plagiarism Detection

IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.

 

EDITORIAL BOARD

CHUDE NKIRU PATRICIA
Nigeria
Dr. Swamy KRM
India
Dr. Abdul Hannan A.M.S
Saudi Arabia.
Luai Farhan Zghair
Iraq
Hasan Ali Abed Al-Zu’bi
Jordanian
Fredrick OJIJA
Tanzanian
Firuza M. Tursunkhodjaeva
Uzbekistan
Faraz Ahmed Farooqi
Saudi Arabia
Eric Randy Reyes Politud
Philippines
Elsadig Gasoom FadelAlla Elbashir
Sudan
Eapen, Asha Sarah
United State
Dr.Arun Kumar A
India
Dr. Zafar Iqbal
Pakistan
Dr. SHAHERA S.PATEL
India
Dr. Ruchika Khanna
India
Dr. Recep TAS
Turkey
Dr. Rasha Ali Eldeeb
Egypt
Dr. Pralhad Kanhaiyalal Rahangdale
India
DR. PATRICK D. CERNA
Philippines
Dr. Nicolas Padilla- Raygoza
Mexico
Dr. Mustafa Y. G. Younis
Libiya
Dr. Muhammad shoaib Ahmedani
Saudi Arabia
DR. MUHAMMAD ISMAIL MOHMAND
United State
DR. MAHESH SHIVAJI CHAVAN
India
DR. M. ARUNA
India
Dr. Lim Gee Nee
Malaysia
Dr. Jatinder Pal Singh Chawla
India
DR. IRAM BOKHARI
Pakistan
Dr. FARHAT NAZ RAHMAN
Pakistan
Dr. Devendra kumar Gupta
India
Dr. ASHWANI KUMAR DUBEY
India
Dr. Ali Seidi
Iran
Dr. Achmad Choerudin
Indonesia
Dr Ashok Kumar Verma
India
Thi Mong Diep NGUYEN
France
Dr. Muhammad Akram
Pakistan
Dr. Imran Azad
Oman
Dr. Meenakshi Malik
India
Aseel Hadi Hamzah
Iraq
Anam Bhatti
Malaysia
Md. Amir Hossain
Bangladesh
Ahmet İPEKÇİ
Turkey
Mirzadi Gohari
Iran